Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

159.88 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 292
Open 159.88
Bid (Size) 159.30 (1)
Ask (Size) 160.11 (1)
Prev. Close 159.88
Today's Range 159.88 - 159.88
52wk Range 143.13 - 175.60
Shares Outstanding 2,628,679,824
Dividend Yield 2.98%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Medicare Costs For Johnson & Johnson's Psoriasis Drug Stelara Double When Obtained at Pharmacies
Medicare beneficiaries face higher costs for Johnson & Johnson's Stelara due to a shift in coverage from Part B to Part D. The OIG report shows a nearly tenfold increase in Medicare spending on... 
Via Benzinga
Exploring NYSE:JNJ's dividend characteristics.
Why the dividend investor may take a look at JOHNSON & JOHNSON (NYSE:JNJ). 
Via Chartmill

Performance

YTD
-0.06%
-0.06%
1 Month
+7.13%
+7.13%
3 Month
+5.73%
+5.73%
6 Month
+1.29%
+1.29%
1 Year
-7.82%
-7.82%

More News

Read More
2 Healthcare Stocks to Buy Hand Over Fist in August
Via The Motley Fool
3 High-Yield Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Nasdaq Sell-Off: 5 Unstoppable Stocks to Buy That Can Protect Your Principal and Grow Your Wealth in an Unpredictable Market
Via The Motley Fool
Looking At Johnson & Johnson's Recent Unusual Options Activity
Via Benzinga
Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
A Closer Look at 14 Analyst Recommendations For Johnson & Johnson
Via Benzinga
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
Via Investor Brand Network
The 3 Best Dividend Aristocrats to Buy for Sustainable Income: August 2024
Via InvestorPlace
3 Dividend Growth Stocks to Buy Hand Over Fist in August
Via The Motley Fool
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
Via FinancialNewsMedia
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
From FN Media Group LLC
Via GlobeNewswire
3 Dividend Growth Stocks to Accumulate on Dips: August Edition
Via InvestorPlace
The Market's Excessive Recession Fears
Via Talk Markets
Topics Economy
Exposures Economy
Large Cap Biopharma And Healthcare, A Port In A Storm
Via Talk Markets
3 Defensive Stocks Weathering the Market Storm
Via MarketBeat
Topics Economy Stocks
Exposures Economy US Equities
The S&P 500 Had Its Worst July in a Decade. Should You Really Buy Stocks Now?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now
Via The Motley Fool
Forget Johnson & Johnson: Another Healthcare Giant Is a Much Better Bet for Growth
Via The Motley Fool
Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore
Via InvestorPlace
7 Leading MedTech Stocks for Next-Gen Health Solutions
Via InvestorPlace
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Via InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Via Benzinga
Q3’s Rising Stars: 3 Dow Stocks for Your Must-Watch List
Via InvestorPlace
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.